Inari Medical, Inc.: M&A transaction — Inari Medical closes LimFlow acquisition; LimFlow reports €20.3M net loss on €938K revenue for 9 months ended Sep 2023

Inari Medical, Inc.

Acquired LimFlow, developer of TADV system for no-option CLTI patients; deal value undisclosed, announced Oct 2023.
LimFlow's audited financials: €20.3M net loss on €938K revenue (nine months through Sep 30, 2023); €18.8M loss on €252K revenue (FY 2022).
As of Sep 30, 2023, LimFlow had €3.1M cash, €1.5M total debt, and accumulated deficit of €101.3M.
Inari filed pro forma combined financials reflecting the acquisition; no additional guidance on future earnings impact provided.

item 9.01 item 2.01 item 7.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Inari Medical, Inc. completed an acquisition involving LimFlow S.A. (closed 2023-11-15).

Action: acquisition
Counterparty: LimFlow S.A.
Closing: 2023-11-15

Exact text from the filing

announced that it closed its acquisition (the “Acquisition”) of LimFlow S.A.

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001531048-24-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.